top of page

AAV Products Highlights

uBriGene has been striving for excellence in the field of plasmid and AAV production for years. With a professional technical team, solid theoretical foundation, and extensive production experience, we have high-quality off-the-shelf AAV products including genes for fluorescent proteins, optogenetics, chemical genetics, calcium indicators, neurotransmitter fluorescent probes, Cre & Flp recombinase, as well as autophagy and Pcsk9 atherosclerosis modeling tools. We offer more than 10 AAV serotypes, more than 40 promoters (broad-spectrum & tissue-specific), as well as constitutive & inducible expression methods to meet different experimental needs.


uBriGene is one of the few CDMO companies experienced in the industrialized production of AAV. We have independently developed AAV-packaging cells, notably the self-innovated, patented 293XS suspension culture cell line.

As the most critical raw materials for AAV production, large-scale production of plasmids is crucial. The whole process of uBriGene plasmid production and fermentation is serum, animal-ingredients, and antibiotics free. The purification steps adopt an innovative and efficient two-step column chromatography process, and plasmid yield can reach 1g/L. We also provide an AAV purification platform for multiple serotypes, with high yield and low empty shell rate, and can be linearly scaled up to 200-500L.

  • Why is a three-tiered cell bank required?
    According to regulations, a complete culture cell bank must be established before GMP-grade plasmid production, including the primary cell bank, the master cell bank and the working cell bank.
  • What is the storage temperature for plasmids? How long can they be stored?
    According to BriGene’s many years of GMP plasmid production experience, the storage temperature of plasmids is -20°C, and the long-term storage stability data can be traced back for more than half a year.
  • Which strain is used to produce plasmids?
    uBriGene uses DH5α or Stbl3 for plasmid production, depending on the customer's choice.
  • Why are plasmids modified for kanamycin resistance?
    Regulations require that the vectors used in gene therapy drugs must not introduce resistance to penicillin.

Other Products

Gene of Interest

Related Services

IIT non-registered clinical study / investigational new drug (IND) application / gene therapy commercialization

bottom of page